Vir Biotechnology, Inc. (VIR)
NASDAQ: VIR · Real-Time Price · USD
7.68
-0.03 (-0.39%)
At close: Feb 3, 2026, 4:00 PM EST
7.60
-0.08 (-1.04%)
After-hours: Feb 3, 2026, 5:44 PM EST
Vir Biotechnology Employees
Vir Biotechnology had 408 employees as of December 31, 2024. The number of employees decreased by 179 or -30.49% compared to the previous year.
Employees
408
Change (1Y)
-179
Growth (1Y)
-30.49%
Revenue / Employee
$41,324
Profits / Employee
-$1,224,640
Market Cap
1.07B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2024 | 408 | -179 | -30.49% |
| Dec 31, 2023 | 587 | 11 | 1.91% |
| Dec 31, 2022 | 576 | 132 | 29.73% |
| Dec 31, 2021 | 444 | 117 | 35.78% |
| Sep 30, 2021 | 395 | 98 | 33.00% |
| Jun 30, 2021 | 367 | 114 | 45.06% |
| Mar 31, 2021 | 340 | 103 | 43.46% |
| Dec 31, 2020 | 327 | 98 | 42.79% |
| Sep 30, 2020 | 297 | 80 | 36.87% |
| Jun 30, 2020 | 253 | 47 | 22.82% |
| Mar 31, 2020 | 237 | 31 | 15.05% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Iovance Biotherapeutics | 838 |
| AbCellera Biologics | 596 |
| Phathom Pharmaceuticals | 427 |
| ARS Pharmaceuticals | 167 |
| EyePoint | 165 |
| CytomX Therapeutics | 121 |
| ORIC Pharmaceuticals | 106 |
| Nanobiotix | 103 |
VIR News
- 19 days ago - Vir Biotechnology, Inc. (VIR) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript - Seeking Alpha
- 22 days ago - Vir Biotechnology Provides Updates on Chronic Hepatitis Delta and Oncology Programs and Upcoming 2026 Clinical Milestones - Business Wire
- 4 weeks ago - Vir Biotechnology to Present at the 44th Annual J.P. Morgan Healthcare Conference - Business Wire
- 7 weeks ago - Vir Biotechnology Grants Norgine Exclusive Commercial License to Chronic Hepatitis Delta Treatment Candidate in Europe, Australia & New Zealand, Including Global Cost Sharing Agreement for Ongoing ECLIPSE Clinical Development Program - Business Wire
- 2 months ago - Vir Biotechnology to Participate in the 8th Annual Evercore Healthcare Conference - Business Wire
- 3 months ago - Vir Biotechnology Announces AASLD The Liver Meeting® Presentation & New England Journal of Medicine Publication of Phase 2 Data Demonstrating Tobevibart & Elebsiran Combination Deliver High Rates of Undetectable HDV RNA with Favorable Safety Profile - Business Wire
- 3 months ago - Vir Biotechnology to Participate in the Jefferies 2025 London Healthcare Conference - Business Wire
- 3 months ago - Vir Biotechnology, Inc. (VIR) Q3 2025 Earnings Call Transcript - Seeking Alpha